1. Percutaneous in vivo gene transfer to the peripheral lungs using plasmid-liposome complexes
- Author
-
Minoru Inage, Suichi Kato, Hidenori Nakamura, Sumito Inoue, Hitonobu Tomoike, Minoru Ito, and Hiroshi Saito
- Subjects
Pulmonary and Respiratory Medicine ,Male ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Physiology ,Genetic enhancement ,Cytomegalovirus ,Biology ,Adenocarcinoma ,Transfection ,Rats, Sprague-Dawley ,In vivo ,Genes, Reporter ,Physiology (medical) ,Pulmonary fibrosis ,Gene expression ,Parenchyma ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Luciferase ,Luciferases ,Lung ,Drug Carriers ,Endothelin-1 ,Genetic transfer ,Cell Biology ,respiratory system ,medicine.disease ,Molecular biology ,respiratory tract diseases ,Rats ,medicine.anatomical_structure ,Liposomes ,Plasmids - Abstract
The purpose of this study was to investigate a new method of in vivo gene transfer to the lung parenchyma by the percutaneous approach. The plasmid that contains the gene for firefly luciferase driven by a cytomegalovirus (CMV) promoter (pCMVL) in combination with cationic lipids was percutaneously injected into the lung parenchyma. Luciferase activities were localized to the lobes of the lung where the plasmids with cationic lipids were injected. Percutaneous injection of the plasmid containing the human endothelin-1 (hET-1) gene driven by a CMV promoter (pRc/CMVhET-1) in combination with cationic lipids into the lungs caused pulmonary fibrosis localized to the injection site in the peripheral lungs. We concluded that percutaneous in vivo gene transfer to the lungs is a unique and important approach to introduce exogenous gene expression in the limited area of the lung parenchyma. This method of gene transfer will be applicable for human gene therapy for targeted areas of peripheral lung and will also be useful to assess the function of the proteins expressed by a gene in the local area of the lungs.
- Published
- 2000